Clinical Trial Update: Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating an HLA-A*0201-restricted peptide vaccine therapy in patients with non-small cell lung cancer; sponsor Tokyo University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HLA-A*0201-restricted peptide vaccine therapy

Snippet

Sponsor: Tokyo University | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN